Cogent Biosciences (COGT) Income from Continuing Operations (2017 - 2020)
Historic Income from Continuing Operations for Cogent Biosciences (COGT) over the last 4 years, with Q4 2020 value amounting to -$11.4 million.
- Cogent Biosciences' Income from Continuing Operations fell 59478.49% to -$11.4 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$82.1 million, marking a year-over-year decrease of 15713.7%. This contributed to the annual value of -$321.7 million for FY2025, which is N/A changed from last year.
- According to the latest figures from Q4 2020, Cogent Biosciences' Income from Continuing Operations is -$11.4 million, which was down 59478.49% from -$57.2 million recorded in Q3 2020.
- Over the past 5 years, Cogent Biosciences' Income from Continuing Operations peaked at $2.3 million during Q4 2019, and registered a low of -$57.2 million during Q3 2020.
- For the 4-year period, Cogent Biosciences' Income from Continuing Operations averaged around -$10.9 million, with its median value being -$8.0 million (2018).
- Per our database at Business Quant, Cogent Biosciences' Income from Continuing Operations soared by 12676.83% in 2019 and then crashed by 59478.49% in 2020.
- Quarter analysis of 4 years shows Cogent Biosciences' Income from Continuing Operations stood at -$6.8 million in 2017, then decreased by 26.77% to -$8.6 million in 2018, then skyrocketed by 126.77% to $2.3 million in 2019, then plummeted by 594.78% to -$11.4 million in 2020.
- Its last three reported values are -$11.4 million in Q4 2020, -$57.2 million for Q3 2020, and -$7.4 million during Q2 2020.